Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study - Andre, T; Tougeron, D; Piessen, G (J Clin Oncol, 2023)
et al.